A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152H CFTR Mutation

Vertex Pharmaceuticals logo

Vertex Pharmaceuticals

Status and phase

Completed
Phase 3

Conditions

Cystic Fibrosis

Treatments

Drug: Placebo
Drug: Ivacaftor

Study type

Interventional

Funder types

Industry

Identifiers

NCT03068312
2017-000457-39 (EudraCT Number)
VX16-770-127

Details and patient eligibility

About

This study will evaluate the efficacy of ivacaftor treatment in subjects with CF 6 years of age and older who have a 3849 + 10KB C→T or D1152H CFTR mutation.

Enrollment

38 patients

Sex

All

Ages

6+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Confirmed diagnosis of CF based on protocol-specified clinical features and at least one of the following: increased sweat chloride level, identification of 2 CF causing mutations, or demonstration of abnormal nasal epithelial ion transport.
  • A 3849 + 10KB C→T or D1152H mutation on at least 1 CFTR allele.
  • FEV1 ≥40% of predicted and ≤105% of predicted at screening.

Exclusion criteria

  • A G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, or R117H mutation.
  • History of any illness or any clinical condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject.
  • Ongoing or prior participation in an investigational drug study within 30 days before the Screening Visit.
  • Protocol-specified abnormal laboratory values at the Screening Visit
  • For subjects <18 years of age at the Screening Visit, evidence of cataract/lens opacity determined to be clinically significant by the ophthalmologist or optometrist during the ophthalmologic examination (OE) at the Screening Visit.
  • Use of any moderate or strong inducers or inhibitors of cytochrome P450 (CYP) 3A, including consumption of certain herbal medications and certain fruit and fruit juices, within 14 days before Day 1.
  • Pregnant, breastfeeding, or planning to become pregnant during the study.
  • Sexually active subjects of reproductive potential must be willing to use appropriate contraception.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Quadruple Blind

38 participants in 2 patient groups

Sequence 1: First Ivacaftor (IVA) Then Placebo
Experimental group
Description:
Participants received IVA 150 milligram (mg) every 12 hours (q12h) for 8 weeks in treatment period 1 followed by placebo matched to IVA for 8 weeks in treatment period 2. A washout period of 8 weeks was maintained between the 2 treatment periods.
Treatment:
Drug: Ivacaftor
Drug: Placebo
Sequence 2: First Placebo Then IVA
Experimental group
Description:
Participants received placebo matched to IVA for 8 weeks in treatment period 1 followed by IVA 150 mg q12h for 8 weeks in treatment period 2. A washout period of 8 weeks was maintained between the 2 treatment periods.
Treatment:
Drug: Ivacaftor
Drug: Placebo

Trial documents
2

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems